Cyclovirobuxin D(Bebuxine) chemical structure
Chemical structureResearch use only
CAT. NO. DCAPI1374Featured

Cyclovirobuxin D(Bebuxine)

Pack Sizes & Prices

TotalUS$275
We match the best price and quality on market.
Product overview

Description & Application

Cyclovirobuxine D (CVB-D) is the main active component of the traditional Chinese medicine Buxus microphylla. Cyclovirobuxine D induces autophagy and attenuates the phosphorylation of Akt and mTOR[1]. Cyclovirobuxine D inhibits cell proliferation of gastric cancer cells through suppression of cell cycle progression and inducement of mitochondria-mediated apoptosis[2]. Cyclovirobuxine D is beneficial for heart failure induced by myocardial infarction[3].

ParameterValue
Chemical NameCyclovirobuxine D
CAS No.860-79-7
Synonyms9,19-CYCLOPREGNANE-3,20-DIAMINE,N,N',4,4,14-PENTAMETHYL-, (3,5,20S)-;CYCLOVIROBUXINE;CYCLOVIROBUXINE D;9,19-cyclo-5-alpha,9-beta-pregnan-16-alpha-ol,4,4,14-trimethyl-3-beta,20-alpha;bebuxine;-bis(methylamino)-;cvb-d;cyclovirobuxind;cyclovirobuxinum D;cyclobuxine D;9,19-Cyclopregnan-16-ol,4,4,14-trimethyl-3, 20-;bis(methylamino)-,(3β,5α,16α,20S)-;(3b,5a,16a,20S)-4,4,14-Trimethyl-3,20-bis(methylamino)-9,19-cyclopregnan-16-ol;9,19-Cyclopregnan-16-ol,4,4,14-trimethyl-3,20-bis(methylamino)-, (3b,5a,16a,20S)-;Cyclovirobuxine-D;(1S,3R,8R,11S,12S,14R,15S,16R)-7,7,12,16-Tetramethyl-6-(methylamino)-15-[(1S)-1-(methylamino)ethyl]p;Cyclovirobuxin D;51GY352868;C26H46N2O;Cyclovirobuxin D (Bebuxine);(3β,5α,16α,20S)-4,4,14-Trimethyl-3,20-bis(methylamino)-9,19-cyclopregnan-16-ol (ACI);1H,19H-Cyclopropa[9,10]cyclopenta[a]phenanthrene, 9,19-cyclopregnan-16-ol deriv. (ZCI);9,19-Cyclo-5α,9β-pregnan-16α-ol, 4,4,14-trimethyl-3β,20α-bis(methylamino)- (7CI, 8CI);(3α,5α,16α,20S)-4,4,14-Trimethyl-3,20-bis(methylamino)-9,19-cyclopregnan-16-ol;NSC 91722;CYCLOVIROBUXINUM D [CHP];HUANWEIHUANGYANGXING D;NCGC00346606-02;(1R,3R,6S,8R,11S,12S,14R,15S,16R)-7,7,12,16-Tetramethyl-6-(methylamino)-15-[(1S)-1-(methylamino)ethyl]pentacyclo[9.7.0.01,3.03,8.012,16]octadecan-14-ol;HY-N0107;9,19-Cyclo-5-alpha,9-beta-pregnan-16-alpha-ol, 4,4,14-trimethyl-3-beta,20-alpha-bis(methylamino)-;CHEMBL3348842;NCGC00346606-01;AS-17717;9,19-CYCLOPREGNAN-16-OL, 4,4,14-TRIMETHYL-3,20-BIS(METHYLAMINO)-, (3.BETA.,5.ALPHA.,16.ALPHA.,20S)-;860-79-7;Q27260897;NSC91722;NS00094267;9,19-CYCLO-5.ALPHA.,9.BETA.-PREGNAN-16.ALPHA.-OL, 4,4,14-TRIMETHYL-3.BETA.,20.ALPHA.-BIS(METHYLAMINO)-;CYCLOVIROBUXINE D [WHO-DD];9,19-Cyclopregnan-16-ol, 4,4,14-trimethyl-3,20-bis(methylamino)-, (3beta,5alpha,16alpha,20S)-;NSC-91722;Cyclovirobuxine D (Bebuxin);MFCD00468040;AKOS015896107;s2402;DTXSID801316983;9,19-Cyclopregnan-16-ol, 4,4,14-trimethyl-3,20-bis(methylamino)-,(3b,5a,16a,20S)-;CyclovirobuxineD;4,4,14-Trimethyl-3alpha,20-bis(methylamino)-9,19-cyclo-5alpha-pregnan-16-ol;(1S,3R,6S,8R,11S,12S,14R,15S,16R)-7,7,12,16-tetramethyl-6-(methylamino)-15-[(1S)-1-(methylamino)ethyl]pentacyclo[9.7.0.01,3.03,8.012,16]octadecan-14-ol;Q-100865;CS-0007794;UNII-51GY352868;CYCLOVIROBUXINE [INCI];SCHEMBL3385409;BRD-K27799744-001-02-8;Cyclovirobuxin D(Bebuxine)?
FormulaC26H46N2O
M.Wt402.656247615814
SMILESC[C@@]12C[C@@H](O)[C@H]([C@H](C)NC)[C@@]1(C)CC[C@@]13C[C@]41CC[C@H](NC)C(C)(C)[C@@H]4CC[C@@H]23
Purity98%
Storage2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Biological Activity

Cyclovirobuxine D (CVB-D) is the main active component of the traditional Chinese medicine Buxus microphylla. Cyclovirobuxine D induces autophagy and attenuates the phosphorylation of Akt and mTOR[1]. Cyclovirobuxine D inhibits cell proliferation of gastric cancer cells through suppression of cell cycle progression and inducement of mitochondria-mediated apoptosis[2]. Cyclovirobuxine D is beneficial for heart failure induced by myocardial infarction[3].

In Vitro

Cyclovirobuxine D (0-240 µM ;24-72 hours) shows a concentration- and time-dependent reduced cell viability after CVB-D treatment, only 10% MGC-803 cells and 20% MKN28 cells are alive at 72 h after treatment with 240 µM[2]. Cyclovirobuxine D (0-120 µM; 48 hours) arrests the cell cycle of gastric cancer cells at S phase in a concentration-dependent manner[2]. Cyclovirobuxine D (0-120 µM; 48 hours) leads to apoptosis in gastric cancer cells in a concentration-dependent manner, especially early stage apoptosis.Cyclovirobuxine D (0-120 µM; 48 hours) causes apoptosis via up-regulation of the apoptosis- related proteins, cleaved Caspase-3 and ratio of Bax/Bcl-2, in gastric cancer cells[2]. Cell Viability Assay[2] Cell Line: MGC-803 and MKN28 cells Concentration: 0, 30, 60, 120 and 240 µM Incubation Time: 24, 48, 72 hours Result: Reduced Cell Viability and Colony Formation Ability of Gastric Cancer Cells Cell Cycle Analysis[2] Cell Line: MGC-803 and MKN28 cells Concentration: 0, 30, 60, and 120 µM Incubation Time: 48 hours Result: Arrested cell cycle progressions of MGC-803 and MKN28 cells. Apoptosis Analysis[2] Cell Line: MGC-803 and MKN28 cells Concentration: 0, 30, 60, and 120 µM Incubation Time: 48 hours Result: Induced apoptosis of MGC-803 and MKN28 cells. Western Blot Analysis[2] Cell Line: MGC-803 and MKN28 cells Concentration: 0, 30, 60, and 120 µM Incubation Time: 48 hours Result: Up-regulated cleaved Caspase-3 and Bax and decreased the expression of Bcl-2 expression.

In Vivo

No in vivo data are provided in the current product source. Contact us for further information.

References & source

DC Chemicals original product information

Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.

Product documentation

Refer to the certificate supplied with your lot for batch-specific release results.

Handling guide

2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Solution calculator

Related research products

Fluzoparib chemical structureDC22228

Fluzoparib

Fluzoparib (SHR-3162) is a novel, potent and orally available inhibitor of PARP; potently inhibited PARP1 enzyme activity and induced DNA double-strand breaks, G2/M arrest and apoptosis in homologous recombination…

View activity & prices
PF-670462 chemical structureDC2086

PF-670462

PF-670462 is a potent and selective inhibitor of casein kinase (CK1ε and CK1δ), with IC50s of 7.7 nM and 14 nM, respectively.

View activity & prices
PBIT chemical structureDC7550

PBIT

PBIT is a specific inhibitor of the Jumonji AT-rich Interactive Domain 1(JARID1) enzymes. PBIT inhibits JARID1B (KDM5B or PLU1 ) histone demethylase an IC50 of about 3 μM . PBIT also inhibits JARID1A and JARID1C with…

View activity & prices
Fenoldopam (mesylate) chemical structureDC9424

Fenoldopam (mesylate)

Fenoldopam(SKF 82526) mesylate is a drug and synthetic benzazepine derivative which acts as a selective D1 receptor partial agonist.Target: D1 ReceptorFenoldopam is a selective dopamine-1 (DA1) agonist with…

View activity & prices
PKG drug G1 chemical structureDC10821

PKG drug G1

PKG drug G1 targets C42 of PKG Iα. PKG drug G1 can couple to vasodilation and blood pressure lowering by a C42 PKG Iα-independent mechanism.

View activity & prices

Cart

Request quotation